Trial Profile

A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of OP-101 (Dendrimer N-acetyl-cysteine) in Patients With Severe COVID-19

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 16 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OP-101 (Primary)
Indications COVID 2019 infections; Inflammation
Focus Adverse reactions; Proof of concept
Acronyms PRANA
Sponsors Ashvattha Therapeutics

Most Recent Events

09 Feb 2023 Status changed from active, no longer recruiting to discontinued.
25 Jul 2022 Results presented in an Ashvattha Therapeutics Media Release.
25 Jul 2022 According to an Ashvattha Therapeutics media release, data published in the peer-reviewed scientific journal Science Translational Medicine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com